Critical care
Is severe COVID linked to leaky-gut plasma markers?
Open access · cc by · source: Europe PMC
Severe COVID-19 showed higher tight-junction permeability and bacterial/fungal translocation markers that tracked systemic inflammation; zonulin was higher in patients who later died.
Study at a glance
- Design
- Cross-sectional — Multi-omic plasma comparison across COVID severity strata plus validation cohort
- N
- N=80 · Main cohort: 60 COVID+ (20 mild/20 moderate/20 severe) + 20 negative controls; markers validated in additional samples
- Population
- Adults with mild–severe COVID-19 and SARS-CoV-2–negative controls (RUMC)
- Outcome
- Plasma gut-permeability and microbial translocation markers vs COVID severity
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Severe disease associated with elevated tight-junction permeability and microbial product translocation markers correlating with inflammation. Plasma zonulin was higher in moderate/severe vs mild/controls and higher among hospitalized patients who died (8/40) vs survivors.
Methodology
Compared multi-omic plasma profiles from 60 SARS-CoV-2–positive patients (mild/moderate/severe) and 20 negative controls, focusing on gut barrier, translocation, inflammation, metabolome, lipidome, and glycome; key markers validated in an independent cohort.
Limitations
Associations do not prove gut leak causes severe COVID; timing at admission cannot establish sequence, and samples are from selected clinical strata.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Severe COVID tracks plasma markers of barrier leak and microbial translocation.
Multi-omic plasma profiling linked severe COVID-19 to higher tight-junction permeability markers and bacterial/fungal product translocation versus milder disease/controls.
Evidence for the claim as stated.
Antibiotics can perturb gut communities with host-cost consequences in model systems.
Antibiotic exposure perturbs gut microbiota and elevates mortality in the cited experimental setting—evidence that community disruption is not neutral for the host.
Scope note — human COVID plasma markers ≠ mouse/antibiotic mortality design
Limits the claim's scope: a different population, assay, or outcome.
Specific taxa and metabolite patterns associate with autoimmunity and metabolic syndrome risk contexts.
Bacteroides dorei dominance before autoimmunity and gut microbiota–metabolite links to metabolic syndrome show community composition correlating with host disease states beyond acute barrier leak.
Scope note — chronic community associations ≠ acute COVID translocation markers
Limits the claim's scope: a different population, assay, or outcome.
Acute viral severity markers, antibiotic perturbation experiments, and chronic microbiota–disease associations should not be collapsed into one “leaky gut causes X” claim.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Acute viral severity markers, antibiotic perturbation experiments, and chronic microbiota–disease associations should not be collapsed into one “leaky gut causes X” claim.
- Supports · Antibiotics hurt bee gut and survival
- Supports · B. dorei rises before T1D autoimmunity
- Supports · Gut microbes, blood metabolites, and metabolic traits
Related papers in this topic
Same topic cluster — not a recommendation engine.